Viriom aims at developing the new generation of HIV therapies and preventive medicines that would not only be safe and effective but also affordable. Viriom believes that the fight to eradicate HIV can only be won by making novel treatments accessible to every patient across the globe.
Viriom’s lead candidate, Elsulfavirine, is an orally bioavailable prodrug of VM-1500A, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI). The results of preclinical and clinical studies indicate that Elsulfavirine is a new promising drug candidate for HIV/AIDS therapy, as well as pre- and post-exposure prophylaxis.
To date, five clinical studies have been completed, in which the drug has shown excellent tolerability, favorable safety profile and high efficacy.
48 and 96 week clinical studies showed that Elsulfavirine 20mg-based regimen in combination with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) was equally efficacious but significantly better tolerated stable to drug-resistant mutations and safer than Efavirenz (EFV) 600 mg-based therapy.
Viriom expects to obtain first market authorizations for Elsulfavirine outside of the US in 2017 and expand commercialization of therapies and preventive medicines with regional and global partners.
Development is underway for Fixed Dose Combination with nucleoside regimen; once-weekly oral sustained release therapy and PrEP; Long Acting Injectable therapy and PrEP, pro-drug tenofovir NRTi and A4b7 inhibitor of HIV transmission/infection.